Podcast Summary: Transformative Advances in Precision Oncology and ADCs

Podcast: Pharma and BioTech Daily
Host: Pharma and BioTech News
Episode Date: October 21, 2025

Overview

This episode offers an in-depth roundup of transformative advances in precision oncology, focusing particularly on antibody drug conjugates (ADCs) and innovative cancer therapeutics. The host explores major clinical milestones, regulatory updates, and significant industry investments that signal a dynamic, patient-focused evolution in pharma and biotech. Listeners are taken through clinical trial breakthroughs, regulatory decisions, investment strategies, and the growing utility of drug repurposing.

Key Discussion Points & Insights

1. Landmark Head-to-Head Trials in ADCs

AstraZeneca & Daiichi Sankyo vs. Gilead: At ESMO Congress 2025, the antibody drug conjugate from AstraZeneca and Daiichi Sankyo outperformed Gilead’s Trodelvy in the first head-to-head global trial targeting TROP2, underlining ADCs’ role in precision medicine and targeted therapy.
- “Their antibody drug conjugate demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head-to-head trial involving TROP2 targeted therapies.” [00:16]

2. Strategic Manufacturing & Investment Moves

Merck's $3 Billion Investment:
- Merck is investing $3 billion in a small molecule plant in Virginia, reflecting a larger $70 billion commitment to expand manufacturing and R&D in the US, crucial for competitiveness and supply chain optimization.
  - “Such strategic investments are crucial for maintaining competitive advantage and ensuring drug while meeting rising demands and streamlining supply chains.” [00:43]

3. Regulatory Milestones

Testspire's Second Approval ([01:03]):
- Amgen & AstraZeneca’s Testspire: Now approved for chronic rhinosinusitis with nasal polyps (second after severe asthma), increasing competitive edge against Dupixent.
  - “The expanded approval showcases the drug's versatility and represents a strategic push to enhance its market presence against competitors like Dupixent...” [01:11]
Keytruda's New Data in Bladder Cancer ([01:25]):
- Pfizer’s combo therapy for muscle invasive bladder cancer showed a 50% reduction in death risk, reinforcing Keytruda’s status as a cornerstone immunotherapy.
  - “The combination therapy reduced the risk of death by 50%...” [01:29]

4. Drug Repurposing Trends

Roche’s Goxiva for Lupus Nephritis ([01:46]):
- Expansion of oncology drugs into autoimmune domains, even late in product lifecycles, reflects the importance of maximizing existing assets.
  - “While this expansion into autoimmune diseases comes late in Goxiva's lifecycle, it highlights a growing trend of capitalizing on established drugs for new therapeutic areas.” [01:49]

5. Highlights in Oncology

AstraZeneca & Daiichi Sankyo's Zenhurtu: Strong early-stage breast cancer data, suggesting a shift in early intervention strategies.
Novartis’ Pluvicto: Shows promise in hormone-sensitive prostate cancer, endorsing radioligand therapies for new indications.
Setbacks: AstraZeneca’s Imfinzi and Lynparza did not meet survival goals in ovarian cancer, underlining clinical and regulatory hurdles.
- “Not all developments have been positive...underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities...” [02:22]

6. Next-Gen ADC Innovation

Tubulus’ Promising Response Rates: Early trials achieved a 59% response rate, attracting high investor interest ([02:32]).
Bioconjugation Capabilities: Cohance Life Sciences invested $10m in NJ Bio to advance GMP bioconjugation, vital for cutting-edge ADC production.

7. Diagnostics & Early Detection

Grail’s Galleri Blood Test: Progresses toward FDA review with improved performance, possibly reshaping cancer screening practices ([02:43]).

8. Broader Trends and Challenges

Investment in R&D and manufacturing, repurposing drugs for new indications, and a push for earlier and more precise interventions characterize the current biotech landscape.
- “These trends are poised to enhance patient care through more precise and effective treatment options while driving innovation in drug development.” [03:05]

9. Further Noteworthy Updates

Roche’s Eye Disease Program: Mixed results in phase III, but FDA filing proceeds based on secondary endpoints ([03:14]).
Giridestrant in Breast Cancer: Demonstrates 62% risk reduction in breast cancer progression ([03:23]).
- “This development highlights SIRDs expanding role in breast cancer therapy, offering hope for improved outcomes.” [03:26]
ACESO/Summit’s EV Onceumab: Outperformed PD-1 inhibitors + chemo in NSCLC first-line settings.
Exelixis’ Zanzolintinib: Reduced death risk by 20% vs. Stivarga/Regorafenib in targeted therapy ([03:40]).

10. Drug Pipeline & Funding Realities

Daiichi Sankyo & Merck’s Ovarian Cancer Drug: Now in phase III—strategic alliances speed modality development.
Pfizer’s Ponsugromab: From heart failure to cachexia in cancer—exemplifying drug repurposing.
Avaxion’s Personalized Melanoma Vaccine: Achieved a 75% objective response; financial constraints have led to downsizing trial plans ([04:05]).
- “Although promising efficacy data could attract future partnerships and investment, furthering development efforts to ultimately benefit patients awaiting novel interventions.” [04:13]

Memorable Quotes & Notable Moments

On ADC Efficacy:
- “Their antibody drug conjugate demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head-to-head trial involving TROP2 targeted therapies.” — Host [00:16]
On Manufacturing Resilience:
- “Such strategic investments are crucial for maintaining competitive advantage and ensuring drug while meeting rising demands and streamlining supply chains.” — Host [00:43]
On Clinical Setbacks:
- “Not all developments have been positive...underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities like the FDA.” — Host [02:22]
On Repurposing Success:
- “This highlights funding challenges impacting design execution in the biotech sector. Although promising efficacy data could attract future partnerships and investment...” — Host [04:13]

Timestamps for Key Segments

00:16 — AstraZeneca/Daiichi Sankyo’s ADC trial triumph
00:43 — Merck’s $3B US manufacturing expansion
01:03 — Testspire’s new FDA indication
01:25 — Keytruda’s 50% mortality reduction in bladder cancer
01:46 — Goxiva’s repurposing for lupus nephritis
02:22 — Oncology trial setbacks (Imfinzi, Lynparza)
02:32 — Tubulus’ 59% ADC response rate
02:43 — Galleri test advances
03:14 — Roche’s mixed eye disease trial results
03:23 — Giridestrant’s 62% progression risk reduction
03:40 — Exelixis’s Zanzolintinib data
04:05 — Avaxion melanoma vaccine efficacy & funding restraints

Conclusion

The episode paints a picture of an industry at the forefront of innovation—driven by precision medicine, strategic investment, and a willingness to repurpose and expand existing therapies. Breakthroughs in ADCs, next-generation diagnostics, and targeted immunotherapy are equipping clinicians with better tools, while persistent challenges in development and funding signal remaining hurdles on the path to patient impact.

Listeners gain actionable insight into not just the latest trials and approvals, but also the business and regulatory strategies shaping tomorrow’s life-changing therapies.

Transcript

A (0:00)

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers and strategic investments. One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody drug Conjugate demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head to head trial involving TROP2 targeted therapies. This reflects the increasing focus on antibody drug conjugates as precision medicine tools that offer targeted treatment options with potentially improved outcomes over traditional chemotherapy. In a move highlighting the ongoing trend of bolstering domestic production capacities, Merck is making a substantial $3 billion investment in a small molecule drug plant in Virginia. This is part of a broader $70 billion commitment to expand manufacturing and R and D capabilities in the U.S. such strategic investments are crucial for maintaining competitive advantage and ensuring drug while meeting rising demands and streamlining supply chains. Turning to regulatory updates, the FDA has approved Amgen and Astrazenecus Testspire for chronic rhinosinusitis with nasal polyps. This marks Testspire's second indication following its initial approval for severe asthma in 2021. The expanded approval showcases the drug's versatility and represents a strategic push to enhance its market presence against competitors like Dupixent in oncology, Merx, Keytruda and Astellas. Pfizer's pads have made headlines with compelling results in muscle invasive bladder cancer. The combination therapy reduced the risk of death by 50%, reinforcing Keytruda's position as a cornerstone immunotherapy across multiple cancer types. This result not only augments treatment options but also signifies the potential for combination regimens to enhance patient outcomes. Roche has expanded the indication of its aging oncology drug Goxiva to treat lupus nephritis, demonstrating strategic repurposing efforts to extend the lifecycle of existing therapies. While this expansion into autoimmune diseases comes late in Goziva's lifecycle, it highlights a growing trend of capitalizing on established drugs for new therapeutic areas. AstraZeneca and Daiichi Sankyozenhurtu showed robust efficacy in early breast cancer treatment, potentially reshaping therapeutic strategies by offering new hope for early intervention. Similarly, Novartis Pluvicto demonstrated promise in slowing hormone sensitive prostate cancer progression, underscoring the potential of radioligand therapies in oncology. However, not all developments have been positive. Astrazeneca faced setbacks when its Imfinzi and Lynparza combination failed to meet survival goals in ovarian cancer, underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities like the fda. The industry is also witnessing significant advancements in next generation ADCs as evidenced by Tubulus's 59% response rate in early clinical trials which has attracted substantial investor interest interest. Additionally, Grail's Galleri cancer blood test is progressing towards FDA review with enhanced performance data, potentially revolutionizing cancer screening and early detection practices. These scientific and regulatory milestones are complemented by strategic investments in bioconjugation technologies. Cohance Life Sciences $10 million investment in NJ Bio to enhance GMP bioconjugation capabilities exemplifies this trend. Such investments are crucial for advancing ADC development which remains a focal point for innovative cancer therapies. Overall, these developments reflect a dynamic phase for the pharmaceutical and biotech sectors characterized by significant scientific advancements, strategic investments in infrastructure and R and D and an emphasis on expanding indications for existing drugs. These trends are poised to enhance patient care through more precise and effective treatment options while driving innovation in drug development. In other news from the pharmaceutical industry, Roche is marking its efforts in eye disease treatment with mixed results from their phase three trials. Despite not meeting the primary endpoint in one study, Roche plans to file for FDA approval. Regardless, this decision reflects a strategic emphasis on potential benefits indicated by secondary endpoints or overall clinical profile, illustrating the complexities of drug development where regulatory strategies must balance imperfect data with clinical need. In oncology updates, Roche presented data on Giridestrant, an oral selective estrogen receptor degrader, which demonstrated a significant reduction in breast cancer progression risk by 62% for hormone receptor positive breast cancer patients. This development highlights sird's expanding role in breast cancer therapy, offering hope for improved outcomes. Antibody drug conjugates continue to be a focal point of innovation at conferences like Esmo. Tubulus's next generation ADC achieved impressive clinical outcomes, reinforcing investor interest. Meanwhile, ACESO and Summit Therapeutics EV onceumab outperformed standard PD1 inhibitors combined with chemotherapy in first line non small cell lung cancer trials, marking significant strides forward within immunotherapy combinations. Exelixis reported promising data for Zanzolintinib, their franchise molecule, showing reduced death risk by 20% compared to Stavarga, positioning it as a potential new standard within targeted cancer therap. This indicates ongoing evolution toward more patient tailored treatments within oncology landscapes. Daiichi Sankyo along with Merck's progress advancing their ovarian cancer into phase three, exemplifies how strategic collaborations drive advancements across treatment modalities. AstraZeneca's confidence within its ADC pipeline despite industry competition, underscores importance proprietary innovation plays maintaining competitive advantages. Pfizer's ongoing research managing cancer related wasting conditions utilizing ponsugromab initially developed heart failure demonstrates drug repurposing potentials addressing complex syndromes, improving quality life among patients living with cancers today. Lastly, Avaxion's personalized vaccine achieved a 75% objective response in advanced melanoma, yet financial constraints led to a reduced trial scope. This highlights funding challenges impacting design execution in the biotech sector. Although promising efficacy data could attract future partnerships and investment, furthering development efforts to ultimately benefit patients awaiting novel interventions.